Regulatory Affairs Strategy Meeting East Coast 2023

The study of GPCR selectivity through docking has illuminated both the power and the limitations of current AI-driven approaches.

Emerging evidence suggests that synonymous codon substitutions can have profound consequences on protein structure, function, and even disease

The continued refinement of AI-driven molecular generation models will be crucial in unlocking the full potential of artificial intelligence in drug discovery.

Wave-transformed molecular representations mark a paradigm shift in how machine learning models process and understand molecular structures.

AI algorithms now design molecules from scratch, optimizing pharmacological profiles through iterative learning.

AI-driven de novo protein design is transforming the way scientists approach molecular engineering.

The transition to low-carbon monoclonal antibody manufacturing is not just an industry imperative—it is a global necessity.

The chemical industry sits at a crossroads: it is both a major contributor to global CO₂ emissions and a potential solution to the carbon crisis.